Investigational Site Number :8400001

New York, New York 10032

1 studies enrolling now · 2 studies all time

What they study most

Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Parkinson's Disease

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation — Stopped early